Literature DB >> 34003419

Disease activity indices in psoriatic arthritis: current and evolving concepts.

Chrysoula G Gialouri1, George E Fragoulis2,3.   

Abstract

Psoriatic arthritis (PsA) is a highly heterogenous disease, with many different clinical manifestations inside or outside of the musculoskeletal system and the skin. It is often accompanied by comorbidities like cardiovascular diseases and mental health disorders. Acute phase reactants are not always elevated and specific markers for diagnosis and/or monitor the disease are lacking thus far. These characteristics possibly reflect the difficulty in agreement about a disease activity index for PsA. Many indices have been proposed over the last years, each of them considering different combinations of disease characteristics. We performed a literature search for relevant articles using PubMed and Embase. No data limits were applied. The keywords "Psoriatic arthritis" OR "PsA" AND "disease activity" AND "index" OR "indices" were used. Reference lists of relevant articles were also reviewed. Articles were also identified through searches of the authors' own files. In this review, we comparatively present the available indices (simple or composite) used for measuring activity in PsA, highlighting their weaknesses, strengths, and disparities. We comment also on the caveats and pitfalls that are encountered in assessment of disease activity, in relation to clinical practice and research. A widely accepted index for measuring disease activity in PsA is lacking. Other parameters, mostly related to patient-reported outcomes and to novel biomarkers might be included in the future, in such indices. Key points • Disease activity in PsA is multiparametric and its assessment is challenging due to many different phenotypes. • Many different indices are currently in use of PsA disease activity assessment. • Each PsA disease activity index has specific pros and cons.

Entities:  

Keywords:  Activity index; Disease activity; Psoriatic arthritis

Year:  2021        PMID: 34003419     DOI: 10.1007/s10067-021-05774-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  49 in total

1.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

Authors:  William Taylor; Dafna Gladman; Philip Helliwell; Antonio Marchesoni; Philip Mease; Herman Mielants
Journal:  Arthritis Rheum       Date:  2006-08

Review 2.  Psoriatic Arthritis.

Authors:  Christopher T Ritchlin; Robert A Colbert; Dafna D Gladman
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

Review 3.  Considerations for the definition of remission criteria in psoriatic arthritis.

Authors:  Philip J Mease; Laura C Coates
Journal:  Semin Arthritis Rheum       Date:  2017-10-31       Impact factor: 5.532

Review 4.  Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison.

Authors:  Joy Feld; Vinod Chandran; Nigil Haroon; Robert Inman; Dafna Gladman
Journal:  Nat Rev Rheumatol       Date:  2018-06       Impact factor: 20.543

Review 5.  Comorbidities associated with psoriatic arthritis: Review and update.

Authors:  Lourdes M Perez-Chada; Joseph F Merola
Journal:  Clin Immunol       Date:  2020-03-27       Impact factor: 3.969

6.  The association of clinical parameters and ultrasound verified inflammation with patients' and physicians' global assessments in psoriatic arthritis.

Authors:  Angelika Lackner; Christina Duftner; Anja Ficjan; Judith Gretler; Josef Hermann; Rusmir Husic; Winfried B Graninger; Christian Dejaco
Journal:  Semin Arthritis Rheum       Date:  2016-06-02       Impact factor: 5.532

7.  ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.

Authors:  D van der Heijde; E Lie; T K Kvien; J Sieper; F Van den Bosch; J Listing; J Braun; R Landewé
Journal:  Ann Rheum Dis       Date:  2008-12-05       Impact factor: 19.103

Review 8.  Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype.

Authors:  Oliver FitzGerald; Muhammad Haroon; Jon T Giles; Robert Winchester
Journal:  Arthritis Res Ther       Date:  2015-05-07       Impact factor: 5.156

9.  Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus.

Authors:  George E Fragoulis; Gerasimos Evangelatos; Nikolaos Tentolouris; Kalliopi Fragkiadaki; Stylianos Panopoulos; George Konstantonis; Alexios Iliopoulos; Katerina Chatzidionysiou; Petros P Sfikakis; Maria G Tektonidou
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-08       Impact factor: 5.346

10.  Measuring disease activity in psoriatic arthritis.

Authors:  Priscilla C H Wong; Ying-Ying Leung; Edmund K Li; Lai-Shan Tam
Journal:  Int J Rheumatol       Date:  2012-12-25
View more
  1 in total

1.  Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice.

Authors:  Chrysoula G Gialouri; Gerasimos Evangelatos; Maria Pappa; Anastasios Karamanakos; Alexios Iliopoulos; Maria G Tektonidou; Petros P Sfikakis; George E Fragoulis
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-05       Impact factor: 3.625

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.